Skip to Content

2017 Federal Register Index

In 2017, the Drug Enforcement Administration published 167 documents.


Document Type Documents Published Subjects Covered
Rule 17 3
Proposed Rule 11 2
Notice 139 15
2017 Federal Register Index

This index provides descriptive entries and Federal Register page numbers for documents published by Drug Enforcement Administration in the daily Federal Register. It includes entries, with select metadata for all documents published in the 2017 calendar year.

Rules

Import and Export Requirements:

List I Chemicals:

Schedules of Controlled Substances:

Extension of Temporary Placement of THJ-2201, AB-PINACA and AB-CHMINACA in Schedule I of the Controlled Substances Act 1
Placement of 10 Synthetic Cathinones into Schedule I 1
Placement of AB-CHMINACA, AB-PINACA and THJ-2201 into Schedule I 1
Placement of Acetyl Fentanyl into Schedule I 1
Placement of Brivaracetam into Schedule V 1
Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in Schedule II 2
Placement of MT-45 into Schedule I 1
Removal of Naldemedine from Control 1
Temporary Placement of 4-Fluoroisobutyryl Fentanyl into Schedule I 1
Temporary Placement of Acryl Fentanyl into Schedule I 1
Temporary Placement of FUB-AMB into Schedule I 1
Temporary Placement of Six Synthetic Cannabinoids into Schedule I 1
Temporary Placement of ortho-Fluorofentanyl, Tetrahydrofuranyl Fentanyl, and Methoxyacetyl Fentanyl into Schedule I 1
Temporary Placement of six synthetic cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) into Schedule I 1

Proposed Rules

Program to Hire Special Assistant United States Attorneys in Targeted Federal Judicial Districts Utilizing Diversion Control Fee Account Funds 1

Schedules of Controlled Substances:

Placement of AB-CHMINACA, AB-PINACA and THJ-2201 into Schedule I 1
Removal of Naldemedine from Control 1
Temporary Placement of 4-Fluoroisobutyryl Fentanyl into Schedule I 1
Temporary Placement of Acryl Fentanyl into Schedule I 1
Temporary Placement of Cyclopropyl Fentanyl into Schedule I 1
Temporary Placement of FUB-AMB into Schedule I 1
Temporary Placement of Fentanyl-Related Substances in Schedule I 1
Temporary Placement of Seven Fentanyl-related Substances in Schedule I 1
Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) into Schedule I 1
Temporary Placement of ortho-Fluorofentanyl, Tetrahydrofuranyl Fentanyl, and Methoxyacetyl Fentanyl into Schedule I 1

Notices

Agency Information Collection Activities; Proposals, Submissions, and Approvals:

Drug Questionnaire 1

Bulk Manufacturers of Controlled Substances; Applications:

AMPAC Fine Chemicals LLC 1
AMPAC Fine Chemicals, LLC 1
AMRI Rensselaer, Inc. 1
Cambrex High Point, Inc. 1
Cayman Chemical Co. 1
Chemtos, LLC 2
Cody Laboratories, Inc. 1
Galephar Pharmaceutical Research, Inc. 1
Halo Pharmaceutical, Inc. 1
Isosciences, LLC 1
Johnson Matthey Pharmaceutical Materials, Inc. 1
Noramco, Inc. 1
Organic Consultants, Inc. 1
Research Triangle Institute 1
Siegfried USA, LLC 1
Siemens Healthcare Diagnostics, Inc. 1
Sigma Aldrich Research Biochemicals, Inc. 1
Specgx LLC 1

Bulk Manufacturers of Controlled Substances; Registrations 3

Bulk Manufacturers of Controlled Substances; Registrations:

Decisions and Orders:

Arnold E. Feldman, M.D. 1
Arnold E. Feldman, MD 1
Binh M. Chung, M.D. 1
ChipRX, L.L.C., d/b/a City Center Pharmacy 1
David D. Moon, D.O. 1
Donald W. Lamoureaux, M.D. 1
Emmanuel O. Nwaokocha, M.D. 1
First Choice Surgery Center of Baton Rouge, LLC 1
Frank D. Li, M.D. 1
Gentry R. Dunlop, M.D. 1
Harinder Takyar, M.D. 1
Janet Carol Dean, M.D. 1
John D. Bray-Morris, M.D. 1
John P. Moore, III, M.D. 1
John Warren Cox, M.D. 1
Josip Pasic, M.D. 1
Judson J. Somerville, M.D. 1
Kofi E. Shaw-Taylor, M.D. 1
Lee B. Drake, M.D. 1
Leia A. Frickey, M.D. 1
Linda M. Shuck, D.O. 1
Lon F. Alexander, M.D. 1
Luis C B Gomez, D.D.S. 1
Marcia L. Sills, M.D. 1
Marcus W. Anderson, M.D. 1
Masters Pharmaceutical, Inc. 1
Michel P. Toret, M.D. 1
Mohammed S. Aljanaby, M.D. 1
Patricia A. Newton, M.D. 1
Paul E. Pilgram, M.D. 1
Peter F. Kelly, D.P.M. 1
Phong Tran, M.D. 1
Raman Popli, M.D. 1
Richard Jay Blackburn, D.O. 1
Richard W. Walker, M.D. 1
Robert Clark Maiocco, M.D. 1
Robert Markman, M.D. 1
Roberto Zayas, M.D. 1
Sassan Bassiri, D.D.S. 1
Shakeel A. Kahn, M.D. 1
Steven Bernhard, D.O. 1
Steven W. Easley, M.D. 1
Warren B. Dailey, M.D. 1
Wesley Pope, M.D. 1
William H. Wyttenbach, M.D. 1
William J. O'Brien, III, D.O. 1
Yoon H. Choi, M.D. 1

Established Aggregate Production Quotas for Schedule I and II Controlled Substances:

Exempt Chemical Preparations under Controlled Substances Act 1

Importers of Controlled Substances; Applications:

ABBVIE LTD; Correction 1
ABBVIE, Ltd. 1
AMRI Rensselaer, Inc. 1
Almac Clinical Services Incorp 1
Anderson Brecon, Inc. 1
Bellwyck Clinical Services 1
Cambrex Charles City 1
Cambrex High Point, Inc. 1
Cambridge Isotope Laboratories 1
Catalent Centers, LLC 1
Cerilliant Corp. 2
Cody Laboratories, Inc. 1
Fisher Clinical Services, Inc. 1
Fresenius Kabi USA, LLC 1
Galephar Pharmaceutical Research, Inc. 1
Hospira 1
Janssen Ortho LLC 1
KVK-Tech, Inc. 1
Mallinckrodt LLC 1
Meda Pharmaceuticals, Inc. 1
Meridian Medical Technologies 1
Mylan Pharmaceuticals, Inc. 2
Mylan Technologies, Inc. 1
Myoderm 1
R and D Systems, Inc. 1
Rhodes Technologies 1
Sharp Clinical Services, Inc. 1
Siegfried USA, LLC 2
Sigma-Aldrich International GMBH 1
Specgx LLC 1
Spex Certiprep Group, LLC 1
Stepan Co. 1
United States Pharmacopeial Convention 1
Unither Manufacturing, LLC 1
VHG Labs DBA LGC Standard Warehouse 1
Whatever LLC 1
Wildlife Laboratories, Inc. 1
Xcelience 1

Importers of Controlled Substances; Registrations 3

Importers of Controlled Substances; Registrations:

Manufacturers of Controlled Substances; Application:

Janssen Pharmaceutical, Inc. 1

Manufacturers of Controlled Substances; Applications:

American Radiolabeled Chemicals 1
Cambrex Charles City 1
Cedarburg Pharmaceuticals 1
Cerilliant Corp. 1
Eli-Elsohly Laboratories 1
Euticals, Inc. 1
Insys Manufacturing, LLC 1
Mallinckrodt, LLC 1
Nanosyn, Inc. 1
National Center for Natural Products Research NIDA MPROJECT 1
Noramco, Inc. 1
Organix, Inc. 1
Patheon Pharmaceuticals, Inc. 1
Stepan Co. 1

Manufacturers of Controlled Substances; Registrations:

Cayman Chemical Co., AMRI Rensselaer, Inc., et al 1

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017 1

Schedules of Controlled Substances: